This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moody, D. E. Articles by Reddy, J. K. Search for Related Content PubMed PubMed Citation Articles by Moody, D. E. Articles by Reddy, J. K.

American Journal of Pathology, Vol 90, 435-450, Copyright © 1978 by American Society for Investigative Pathology

REGULAR ARTICLES

The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome- associated enzymes

DE Moody and JK Reddy

Male Swiss-Webster mice were fed diets containing four hypolipidemic agents which are known to induce proliferation of hepatic peroxisomes. Treatment with all four drugs (clofibrate; its structural analogue, nafenopin; and two drugs structurally unrelated to clofibrate, tibric acid and Wy-14,643) produced a marked hepatomegaly in the mice. The extent of the increase in liver weight correlated well with the increases in total hepatic DNA and in the collective volume of hepatocyte peroxisomes. Treatment with these drugs also produced similar increases in the activities of peroxisome-associated enzymes. The most dramatic increases were noted in the activities of the short- chain (8- to 26-fold) and medium-chain (4- to 11-fold) carnitine acyltransferase. Significant increases were also noted in the activities of catalase (twofold to threefold), alpha-glycerophosphate dehydrogenase (twofold to threefold) and the long-chain carnitine acyltransferase (twofold to fourfold). Activity of the latter enzyme, however, is not known to be associated with peroxisome fractions. Concomitant administration of actinomycin D or cycloheximide with a single oral dose of clofibrate diminished the increases in liver weight and carnitine acyltransferase which occurred with clofibrate treatment alone. The finding that the major increase in activity of peroxisome enzymes occurred in those associated with metabolism of acyl CoA groups supports the hypothesis that the hypolipidemic action of the drugs and the proliferation of hepatic peroxisomes are related functions.

This article has been cited by other articles:

				I. G. Shabalina, T. Panaretakis, A. Bergstrand, and J. W. Depierre Effects of the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid, on apoptosis in human hepatoma HepG2 cells Carcinogenesis, December 1, 1999; 20(12): 2237 - 2246. [Abstract] [Full Text] [PDF]

				F. E. Weber, G. Minestrini, J. H. Dyer, M. Werder, D. Boffelli, S. Compassi, E. Wehrli, R. M. Thomas, G. Schulthess, and H. Hauser Molecular cloning of a peroxisomal Ca2+-dependent member of the mitochondrial carrier superfamily PNAS, August 5, 1997; 94(16): 8509 - 8514. [Abstract] [Full Text] [PDF]

				J. Ashby, A. Brady, C.R. Elcombe, B.M. Elliott, J. Ishmael, J. Odum, J.D. Tugwood, S. Kettle, and I.F.H. Purchase Mechanistically-based Human Hazard Assessment of Peroxisome Proliferator-induced Hepatocarcinogenesis Human and Experimental Toxicology, January 1, 1994; 13(2_suppl): S1 - S117. [PDF]

				K.N. Woodward Phthalate Esters, Cystic Kidney Disease in Animals and Possible Effects on Human Health: A Review Human and Experimental Toxicology, January 1, 1990; 9(6): 397 - 401. [Abstract] [PDF]

				N. D. Lalwani, M. Kumudavalli Reddy, S. A. Qureshi, C. R. Sirtori, Y. Abiko, and J. K. Reddy Evaluation of Selected Hypolipidemic Agents for the Induction of Peroxisomal Enzymes and Peroxisome Proliferation in the Rat Liver Human and Experimental Toxicology, January 1, 1983; 2(1): 27 - 48. [Abstract] [PDF]

				M.K. Reddy, N.D. Lalwani, S.A. Qureshi, and J.K. Reddy Induction of Hamster Hepatic Peroxisomal {beta}-oxidation and Peroxisome Proliferation-associated 80000 mol. wt. Polypeptide by Hypolipidemic Drugs Human and Experimental Toxicology, March 1, 1982; 1(2): 135 - 147. [Abstract] [PDF]